No Data
BTIG Initiates Lyra Therapeutics(LYRA.US) With Hold Rating
BTIG Keeps Their Hold Rating on Lyra Therapeutics (LYRA)
Analysts Offer Insights on Healthcare Companies: Inogen (INGN) and Lyra Therapeutics (LYRA)
Lyra Therapeutics Announces It Will Present 52-Week Extension Stage Results For ENLIGHTEN 1 Phase 3 Study For LYR-210 For The Treatment of Chronic Rhinosinusitis At COSM May 14-18 2025 In New Orleans
Lyra Therapeutics GAAP EPS of -$0.13 Beats by $0.01, Revenue of $0.18M Beats by $0.02M
Lyra Therapeutics | 10-Q: Q1 2025 Earnings Report
loading...